Previous 10 | Next 10 |
2023-08-09 08:14:47 ET Agile Therapeutics press release ( NASDAQ: AGRX ): Q2 Non-GAAP EPS of -$3.10 beats by $1.85 . Revenue of $5.5M (+158.2% Y/Y) beats by $0.87M . Twirla Demand and Factory Sales Up 24% and 42% Respectively in Second Quarter 2023 Compared to ...
Twirla Delivers Second Quarter 2023 Net Revenue of $5.5 Million, a 44% Increase from First Quarter 2023 Twirla Demand and Factory Sales Up 24% and 42% Respectively in Second Quarter 2023 Compared to First Quarter 2023 Gross Margin Grows to 58% in Second Quarter 2023 from 47% in Fi...
2023-08-08 14:25:54 ET Agile Therapeutics ( NASDAQ: AGRX ) is scheduled to announce Q2 earnings results on Wednesday, August 9th, before market open. The consensus EPS Estimate is -$4.95 (-82.7% Y/Y) and the consensus Revenue Estimate is $4.63M (+120.5% Y/Y). Over the ...
2023-08-08 10:46:10 ET Major earnings expected before the bell on Wednesday include: Brookfield Asset Management ( BAM ) 3D Systems ( DDD ) PENN Entertainment ( PENN ) Roblox ( RBLX ) Sony Group ( SONY ) For further details see: Notable ea...
PRINCETON, N.J., July 26, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced it will report second quarter 2023 financial results before the market open on Wednesday, August 9, 2023. Following the release, the Company will hos...
PRINCETON, NJ / ACCESSWIRE / July 19, 2023 / Agile Therapeutics, Inc.'s (NASDAQ:AGRX) partnership with Afaxys Pharma is expected to play a key role in propelling the women's healthcare company toward its $25-$30 million net annual revenue target for 2023. The companies teamed up last year to...
PRINCETON, NJ / ACCESSWIRE / July 18, 2023 / This month, Agile Therapeutics, Inc. (NASDAQ:AGRX) announced partnerships with FPA Women's Health and vitaCare Prescription Services that will expand access to Twirla® (levonorgestrel and ethinyl estradiol) transdermal system, its l...
PRINCETON, NJ / ACCESSWIRE / July 11, 2023 / - In June, President Biden issued an Executive Order on Strengthening Access to Affordable, High-Quality Contraception and Family Planning Services . It directs the Secretaries of Health and Human Services (HHS), Labor and the Treasury to issue new...
PRINCETON, NJ / ACCESSWIRE / July 5, 2023 / H.C. Wainwright & Co, reiterated its buy rating on Agile Therapeutics, Inc. (NASDAQ:AGRX) this month, setting a price target of $12 per share. The $12 price target is based on the 1:50 reverse split and the $7.5 million raised in Agile's publ...
Agile Says Growing Demand For Twirla (levonorgestrel and ethinyl estradiol ) transdermal system Is Helping It Stay On Track to Hit $25-$30 Million Net Revenue PRINCETON, NJ / ACCESSWIRE / July 3, 2023 / Agile Therapeutics (NASDAQ:AGRX) announced the closing of its public offering in May....
News, Short Squeeze, Breakout and More Instantly...
Agile Therapeutics Inc. Company Name:
AGRX Stock Symbol:
NASDAQ Market:
Agile Therapeutics Inc. Website:
First Quarter Net Revenue Increased 58% and Factory Sales Increased 3% from Fourth Quarter 2023 Twirla First Quarter 2024 Demand Rebounded 18% from Fourth Quarter 2023 PRINCETON, N.J., May 15, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Pink: AGRX), a women's healthcare com...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
Full Year 2023 Net Revenue Increased 80% from 2022 While OPEX Decreased 33% Twirla Demand and Factory Sales Up 121% and 114% Respectively in 2023 vs 2022 Company Completes Pay-Off of Debt Facility in First Quarter 2024 Twirla Demand Expected to Rebound in First Quarter 2...